New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 28, 2012
12:43 EDTEBSEmergent BioSolutions secures U.S. commercial rights to influenza vaccine
Emergent BioSolutions announced that it has signed a license agreement with VaxInnate Corporation under which Emergent acquired the exclusive right to manufacture and sell VaxInnate's pandemic influenza vaccine candidate in the United States. The product candidate, a recombinant vaccine, has the potential to be produced quickly, at high yields and in a cost-effective manner. This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority.
News For EBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
16:08 EDTEBSEmergent BioSolutions reaffirms outlook for 2015
Emergent BioSolutions reaffirms its previous 2015 forecast of total revenues of $510M-$540M, driven by BioThrax sales which are anticipated to be between $270M-$285M. The company also forecasts full year 2015 GAAP net income of $50M-$60M and adjusted net income of $60M-$70M.
16:06 EDTEBSEmergent BioSolutions sees Q1 revenue $62M-$62M, one estimate $51.5M
Subscribe for More Information
16:06 EDTEBSEmergent BioSolutions resumes full manufacturing operations of BioThrax
Emergent BioSolutions announced that it has resumed full manufacturing operations of BioThrax after completing its internal manufacturing investigation of foreign particles discovered in a limited number of vials in two manufactured BioThrax lots. It stated, "Following a comprehensive assessment, the company has identified a supplier component as the most probable root cause. As a result, the company is implementing certain targeted corrective and preventive actions in the operations of its suppliers and contract manufacturers, as well as its own operations. The investigation concluded that there was no impact to any BioThrax in distribution or to any of the company's other products or manufacturing operations, including the company's Building 55 operations and plans for licensure."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use